The Journal of Leukocyte Biology is launching the COVID–19 and Related Topics Special Initiative. This dedicated open-access track with accelerated review cycle will provide quick publication of short reports on leukocyte biology-related research to advance our understanding of host pathophysiology, defense/resistance, immune response and diseases related to SARS-CoV–2. Accepted manuscripts will be published online immediately.

Submit Now

Types of submissions accepted include: A new short-article format designed to expedite reporting, review, and publication (Concise Reports). Articles should be between 1000-1800 words, with up to 2 figures/tables. Or follow JLB’s existing article formats: Brief Conclusive Report, full-length Articles, full-length or Mini Reviews, Technical Advances, Hybrid Reviews. For more information see the JLB Author Guidelines.

Review: An expedited peer review will be conducted, with a decision of “accept”, “accept with minor revisions”, or “reject” rendered within 14–21 days.

Accepted articles: Immediate online open-access, placed in next regular JLB issue, assembled into a “living virtual issue” on the JLB website, featured in JLB social media and Wiley’s COVID–19 online publication list.

Fees: Open access fees (usually $2,800) will be waived for this special initiative (publication fees still apply: $1,700 for SLB members, $1,950 for non-members). Articles will be accepted until December 31, 2021.

Call for Submission (new format available):
COVID–19 and Related Topics
Special Initiative
See full call for papers details here...

@JLB_journal
Click for full information or email with questions